MetaADEDB 2.0 @ LMMD
Isosorbide
(KLDXJTOLSGUMSJ-JGWLITMVSA-N)
Structure
SMILES
O[C@@H]1CO[C@H]2[C@@H]1OC[C@@H]2O
Type(s)
Approved; Investigational
Molecular Formula:
C6H10O4
Molecular Weight:
146.141
Log P:
-1.4942
Hydrogen Bond Acceptor:
4
Hydrogen Bond Donor:
2
TPSA:
58.92
CAS Number(s):
652-67-5
Synonym(s)
1.
Isosorbide
2.
Dianhydrosorbitol
External Link(s)
MeSHD007547
PubChem Compound12597
ChEBI6060
CHEMBLCHEMBL1200660
DrugBankDB09401
DrugCentral1501
KEGGdr:D00347
Therapeutic Target DatabaseD0S6KI
ZINC18284778
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1HeadacheFAERS: 6SIDER
US FAERS
2Incorrect dose administeredFAERS: 3US FAERS
3MalaiseFAERS: 3US FAERS
4NauseaFAERS: 3SIDER
US FAERS
5VomitingFAERS: 3SIDER
US FAERS
6Chest PainFAERS: 2OFFSIDES
US FAERS
7Toxicity to various agentsFAERS: 2US FAERS
8UrticariaFAERS: 2US FAERS
9Blood potassium decreasedFAERS: 1US FAERS
10Burning sensationFAERS: 1US FAERS
11DehydrationFAERS: 1OFFSIDES
US FAERS
12DisorientationFAERS: 1US FAERS
13Drug dispensing errorFAERS: 1US FAERS
14Drug ineffectiveFAERS: 1OFFSIDES
US FAERS
15FlushingFAERS: 1SIDER
US FAERS
16General physical health deteriorationFAERS: 1OFFSIDES
US FAERS
17HypotensionFAERS: 1SIDER
US FAERS
18Incorrect product dosage form administeredFAERS: 1US FAERS
19Medication residue presentFAERS: 1US FAERS
20Peripheral swellingFAERS: 1US FAERS
21Pharmaceutical product complaintFAERS: 1US FAERS
22PresyncopeFAERS: 1US FAERS
23Product quality issueFAERS: 1US FAERS
24Product solubility abnormalFAERS: 1US FAERS
25PruritusFAERS: 1US FAERS
26ShockFAERS: 1SIDER
US FAERS
27SwellingFAERS: 1US FAERS
28SyncopeFAERS: 1SIDER
US FAERS
29VertigoFAERS: 1US FAERS
30Abdominal AbscessOFFSIDES
31Abdominal PainOFFSIDES
32Abdominal discomfortOFFSIDES
33Abnormal visionOFFSIDES
34Acid refluxOFFSIDES
35Acute Coronary SyndromeOFFSIDES
36Acute myocardial infarctionOFFSIDES
37AgoraphobiaOFFSIDES
38AneurysmOFFSIDES
39Angina PectorisSIDER
40AnhedoniaOFFSIDES
41Anorexia2602249CTD
OFFSIDES
42Anticonvulsant drug level above therapeuticOFFSIDES
43AnxietyOFFSIDES
44Aortic AneurysmOFFSIDES
45Application site erythemaOFFSIDES
46Application site rashOFFSIDES
47Application site vesiclesOFFSIDES
48ArteriosclerosisOFFSIDES
49ArthropathyOFFSIDES
50AstheniaOFFSIDES
51AtaxiaOFFSIDES
52AtherosclerosisOFFSIDES
53Axonal neuropathyOFFSIDES
54Bladder spasmOFFSIDES
55Blood GlucoseOFFSIDES
56Blood cholesterolOFFSIDES
57Blood creatinine increasedOFFSIDES
58Blood glucose decreasedOFFSIDES
59Blurred visionOFFSIDES
60BradycardiaOFFSIDES
SIDER
61BronchitisOFFSIDES
62BursitisOFFSIDES
63CalcinosisOFFSIDES
64Cardioactive drug level increasedOFFSIDES
65Carotid artery occlusionOFFSIDES
66CataractOFFSIDES
67Chemical and Drug Induced Liver Injury2602249CTD
68Chest wall painOFFSIDES
69Choking sensationOFFSIDES
70Chronic Fatigue SyndromeOFFSIDES
71Chronic Obstructive Airway DiseaseOFFSIDES
72Chronic left ventricular failureOFFSIDES
73Clostridium colitisOFFSIDES
74Cognitive deteriorationOFFSIDES
75Concomitant disease progressionOFFSIDES
76ConfabulationOFFSIDES
77Delusional disorder, persecutory typeOFFSIDES
78Depressed moodOFFSIDES
79DermatitisSIDER
80DiabetesOFFSIDES
81Diabetes mellitus inadequate controlOFFSIDES
82Diastolic dysfunctionOFFSIDES
83DiverticulumOFFSIDES
84DizzinessOFFSIDES
SIDER
85Drug toxicityOFFSIDES
86Dry skinOFFSIDES
87DyspepsiaOFFSIDES
88Economic problemOFFSIDES
89Ejection Fraction DecreasedOFFSIDES
90Electrocardiogram ST-T changeOFFSIDES
91Emotional distressOFFSIDES
92Erythema2602249CTD
93Exfoliative rashOFFSIDES
94Extremity contractureOFFSIDES
95Fatty LiverOFFSIDES
96Fluid overloadOFFSIDES
97GranulocytosisOFFSIDES
98Heparin-induced thrombocytopeniaOFFSIDES
99HepatosplenomegalyOFFSIDES
100HerniaOFFSIDES
101HyperpigmentationOFFSIDES
102Hypoaesthesia facialOFFSIDES
103HypoparathyroidismOFFSIDES
104HypotensiveSIDER
105Ileal ulcerOFFSIDES
106ImmobileOFFSIDES
107Impaired work abilityOFFSIDES
108Infusion site mobility decreasedOFFSIDES
109Intraductal papilloma of breastOFFSIDES
110Joint Range of Motion DecreasedOFFSIDES
111Joint sprainOFFSIDES
112Left Ventricular HypertrophyOFFSIDES
113LightheadednessSIDER
114Medication residueOFFSIDES
115Mental status changesOFFSIDES
116MicrocytosisOFFSIDES
117Mitral Valve StenosisOFFSIDES
118Muscle tightnessOFFSIDES
119Musculoskeletal discomfortOFFSIDES
120Musculoskeletal stiffnessOFFSIDES
121MyosclerosisOFFSIDES
122Nephrogenic Fibrosing DermopathyOFFSIDES
123Nicotine DependenceOFFSIDES
124Nodule on extremityOFFSIDES
125ObstructionOFFSIDES
126OnycholysisOFFSIDES
127PainOFFSIDES
128Patellofemoral Pain SyndromeOFFSIDES
129Pharyngolaryngeal PainOFFSIDES
130PresbyopiaOFFSIDES
131Prescribed overdoseOFFSIDES
132Pressure of speechOFFSIDES
133Reaction to medical agent preservativesOFFSIDES
134Rebound hypertensionSIDER
135Reflex tachycardiaSIDER
136Renal Insufficiency2602249CTD
137Renal cystOFFSIDES
138Respiratory FailureOFFSIDES
139Sinus bradycardiaOFFSIDES
140Skin IndurationOFFSIDES
141Skin hypertrophyOFFSIDES
142Skin tightnessOFFSIDES
143Synovial CystOFFSIDES
144TachycardiaSIDER
145TinnitusCanada Vigilance: 1Canada Vigilance
146Tongue blisteringOFFSIDES
147Venous InsufficiencyOFFSIDES
148Ventricular Fibrillation10908272CTD
149Withdrawal hypertensionSIDER
150jaundice2602249CTD
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120234

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.